BDRX Latest Press Releases

-- April 2, 2026 --

Biodexa Announces Partnership with Syngene To Manufacture MTX240 GMP Clinical Trial Supplies Globe Newswire 8:30 AM

-- March 27, 2026 --

Preliminary Results for the Year Ended 31 December 2025 Globe Newswire 5:00 PM

-- March 23, 2026 --

Biodexa Launches Global Early Access Program for eRapa for FAP Patients Through Strategic Partnership with Tanner Pharma Group Globe Newswire 8:30 AM

-- March 18, 2026 --

ADR Ratio Change Globe Newswire 5:00 PM

-- March 9, 2026 --

Biodexa Announces Support for Life's a Polyp Foundation First U.S. Patient Advocacy Group for FAP Patients Globe Newswire 8:30 AM

-- February 19, 2026 --

Biodexa Licenses Phase 1 Ready Drug Candidate from Otsuka for Rare Stomach Cancer ACCESS Newswire 7:30 AM

-- February 4, 2026 --

Biodexa Announces Exclusive License of Otsuka's OPB-171775, a potent Phase 1 ready Molecular Glue for GIST Globe Newswire 8:30 AM

-- January 5, 2026 --

Appointment of Fiona Sharp to the Board as Chief Financial Officer and Company Secretary Globe Newswire 8:30 AM

-- December 18, 2025 --

Biodexa Announces Pricing of $10 Million Public Offering Globe Newswire 8:30 AM

-- December 1, 2025 --

Biodexa Announces Enrolment of First European Patients into Pivotal Phase 3 Serenta Trial in FAP Globe Newswire 8:30 AM

-- November 24, 2025 --

Biodexa Activates First European Site for Registrational Phase 3 Serenta Trial in FAP Globe Newswire 8:30 AM

Market Data Delayed 15 Minutes

Questions? Feedback?Olark live chat software